Osmotic fragility test
Osmotic fragility is a blood test to detect whether red blood cells are more likely to break down.
How is the Test Performed?
A blood sample is needed.
In the laboratory, red blood cells are tested with a solution that makes them swell in order to determine how fragile they are.
Preparation for the Test
No special preparation is necessary for this test.
How the Test will Feel
When the needle is inserted to draw blood, some people feel moderate pain. Others feel only a prick or stinging. Afterward, there may be some throbbing or a slight bruise. This soon goes away.
Why is the Test Performed?
This test is done to detect hereditary spherocytosis and thalassemia. Hereditary spherocytosis makes red blood cells more fragile than normal. With thalassemia, red blood cells are more fragile than normal, but a larger number are less fragile than normal.
Normal Results for Osmotic fragility test
A negative test is normal.
Normal value ranges may vary slightly among different laboratories. Some labs use different measurements or test different samples. Talk to your doctor about the meaning of your specific test results.
What Abnormal Results Mean
- Hereditary spherocytosis
Osmotic fragility test Risks
Veins and arteries vary in size from one patient to another, and from one side of the body to the other. Obtaining a blood sample from some people may be more difficult than from others.
Other risks associated with having blood drawn are slight, but may include:
- Excessive bleeding
- Fainting or feeling light-headed
- Hematoma (blood accumulating under the skin)
- Infection (a slight risk any time the skin is broken)
Elghetany MT, Banki K. Erythrocytic disorders. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 22nd ed. Philadelphia, Pa: Elsevier Saunders; 2011:chap 32.
Gallagher PG, Jarolim P. Red blood cell membrane disorders. In: Hoffman R, Benz EJ Jr, Silberstein LE, et al., eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, Pa: Elsevier Saunders; 2012:chap 43.
|Review Date: 2/24/2014
Reviewed By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.